CBCarlos Marcelo de Barros

Carlos Marcelo de Barros

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Carlos Marcelo de Barros has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Total Pain in People With Trigeminal Neuralgia: A Scoping Review

    by Cremilson de Paula Silva, Angela Bezerra Soares Perlamagna, Marina Quintino Silva, Alice Regina Costa Barbosa, Carlos Marcelo de Barros, Ana Cláudia Mesquita Garcia

  • Open Access

    Digitally Enabled Discharge Quality After Neurosurgical Traumatic Brain Injury: A 10-Year Cohort from a Brazilian Public Tertiary Center

    by Roberto Salvador Souza Guimarães, Victoria Ragognete Guimarães, Carlos Marcelo Barros, Maísa Ribeiro Pereira Lima Brigagão, Francisca Rego

    Background/Objectives: Safe discharge after neurosurgical traumatic brain injury (TBI) depends on documented counseling and appropriate referrals, yet real-world fidelity is uncertain in resource-constrained settings. We quantified discharge process quality and identified digitally actionable gaps. Methods: The sample for this study was a retrospective cohort of 559 consecutive neurosurgical TBI patients discharged from a Brazilian public tertiary center (2012–2022). Data were abstracted from electronic health records. The primary outcome was documentation of warning sign counseling at discharge. Proportions are reported with exact Clopper–Pearson 95% confidence intervals. Results: The median age was 66 years (IQR 47–79.5); 78.5% were male and most received care under the public health system. Subdural hematoma predominated; hematoma drainage was the most frequent procedure. Warning sign counseling was documented in 16.1% of cases (89/559; 95% CI 13.2–19.5), and no palliative care referrals were recorded. Conclusions: A low baseline for a safety-critical discharge element exposes an immediately actionable target. Embedding discharge order sets with mandatory counseling fields in the EHR, clinical decision support prompts for palliative care screening and follow-up, and QR-coded patient handouts represent a pragmatic path to improve discharge quality and end-of-life readiness in the digital era.

  • Open Access

    Cooled Radiofrequency at Five Revised Targets for Short-Term Pain and Physical Performance Improvement in Elderly Patients with Knee Osteoarthritis: A Prospective Four-Case Reports

    by Rafaela F. Rodrigues, Carlos Marcelo de Barros, André A. V. Lima, Felipe T. Vilela, Vanessa B. Boralli

    Background and Objectives: Osteoarthritis (OA) is a common cause of chronic pain. In refractory cases, cooled radiofrequency (CRF) of the genicular nerves is indicated. However, recent studies suggest that traditional targets may be insufficient, proposing the inclusion of the recurrent fibular nerve and the infrapatellar branch of the saphenous nerve. This study reports a prospective four-case series evaluating short-term outcomes of CRF at five revised targets in elderly Brazilian patients. Case Report: The study (CAAE No.: 55647722.5.0000.5142) included four patients (three women, one man; mean age 73.8 years) with moderate to severe refractory knee pain underwent diagnostic nerve block followed by ultrasound-guided CRF. After 30 days, three patients reported pain reduction, including two who experienced substantial improvement. One patient maintained severe pain. Improvements in physical performance, knee flexion, and extension were observed in patients who responded clinically, while individuals with coexisting myofascial pain showed limited functional gains. One patient experienced mild transient pruritus. In this prospective case series, CRF applied to five revised targets appeared feasible and well tolerated, with short-term improvement in pain and function in some patients. These preliminary descriptive findings support further investigation in larger controlled studies.

  • Effectiveness of epidural morphine for the treatment of cancer pain in patients with gastrointestinal neoplasm—a systematic review

    by Yasmim Jianjulio Nassif, Maria Elisa Zanin, Joselin Valeska Martinez-Sobalvarro, Carlos Marcelo de Barros, Maurílio Pacheco-Neto, Tiago Marques dos Reis, Márcia Helena Miranda Cardoso-Podestá, Larissa Helena Torres

    One-third of cancer pain patients do not experience adequate pain relief using analgesic ladder by the World Health Organization. Interventional procedures, such as epidural morphine, have been considered. This study aimed to review the literature comparing the effects of epidural administration of morphine with the oral route. This systematic review included randomized controlled trials (RCTs) conducted with patients with gastrointestinal neoplasm. A search was conducted on PubMed, EMBASE, Web of Science, Scopus, Cochrane Library, and CINAHL databases to identify studies published up to May 2023. The retrieved study was evaluated using the Risk of Bias 2 (RoB 2) tool and qualitatively synthesized. The certainty of evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach (Prospero: CRD42021264728). Only one RCT, a crossover trial, was included in this systematic review. The study was conducted with ten participants (one withdrawal) and reported a statistically significant difference between both subcutaneous and epidural morphine solutions and oral morphine. The adverse events were not described. The included study presents some concerns of bias and low certainty of evidence on the effectiveness and security of epidural morphine administration. The available literature does not suffice to elucidate whether morphine administration via the epidural route is more effective than other routes. Further RCTs are necessary to improve the level of evidence on the effectiveness and risk-benefit of epidural morphine in the management of cancer pain in gastrointestinal neoplasm patients.

  • Open Access

    Tapentadol, an opioid as a strategy for the treatment of chronic pain? A narrative review

    by Alessandra Oliveira Silva, Danielle Aparecida de Oliveira Marrafon, Ana Flávia Amorim, Carlos Marcelo de Barros, Ricardo Radighieri Rascado, Carla Speroni Ceron, Tiago Marques dos Reis, Márcia Helena Miranda Cardoso Podestá, Daniel Augusto de Faria Almeida, Larissa Helena Torres, et al.

    Chronic pain affects approximately 30 % of the world population. Tapentadol can be an analgesic option for patients who do not respond adequately to commonly used opioids. This study reviewed the general aspects of Tapentadol pain treatment and its possible association with increased oxidative stress, as well as the benefits of its association with antioxidant substances. The search was carried out in the Medline (Pubmed), Scopus, Web of Science, and Google academic databases, including studies since the registration of the drug in 2008. The selected articles were those related to the use of Tapentadol for chronic moderate to severe pain, but not cancer-related pain, in adults and the elderly. Tapentadol is a µ opioid receptors agonist and inhibits noradrenaline reuptake. Although Tapentadol causes fewer adverse effects than other conventional opioids, studies have shown the induction of oxidative stress by this drug, but without having elucidated the mechanisms.

  • Oral pregabalin is effective as preemptive analgesia in abdominal hysterectomy—A randomized controlled trial

    by Fabrício Gomes da Silva, Márcia Helena Miranda Cardoso Podestá, Thayná Coelho Silva, Carlos Marcelo de Barros, Breno Fialho Vitarelli de Carvalho, Tiago Marques dos Reis, Milena Carla Espósito, Danielle Aparecida Ferreira de Oliveira Marrafon, Denismar Alves Nogueira, Sudhir Diwan, et al.

    Postoperative pain is one of the main negative symptoms resulting from surgery and the use of new methods to control this symptom is of ever‐increasing relevance. Opioid‐sparing strategies, such as multimodal analgesia, are trends in this scenario. Pregabalin is a well‐established treatment for neuropathic pain; however, it is still controversial in the surgical context for postoperative analgesia. This study investigated the effect of pregabalin on postoperative analgesia in patients undergoing abdominal hysterectomy. It is a prospective, randomised, double‐blind, placebo‐controlled clinical trial. Female patients undergoing abdominal hysterectomy were randomised to use pregabalin (group P1), 300 mg orally 2 h before surgery, or identical placebo pills (group P0). The main outcome includes the postoperative pain index by visual analogue scale (VAS) and McGill's pain questionnaire. Secondary outcomes include opioid consumption and the presence of adverse effects. A value of p < 0.05 was used to reject type I error. Fifty‐five patients were randomised amongst the groups. Patients in group P1 had lower pain rates by VAS scale, both at rest and in active motion, than group P0. In McGill's questionnaire, patients from group P1 also had lower pain rates (12 × 28.5). There was approximately twice as much opioid consumption amongst patients in group P0. Regarding side effects, there was a difference between the two groups only for dizziness, being more incident in group P1. This study suggests that pregabalin is an important adjuvant drug in treating postoperative pain in patients with abdominal hysterectomy.